查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球基准标记市场
市场调查报告书
商品编码
1217640

2023-2030 年全球基准标记市场

Global Fiducial Markers Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

基准标记，也称为基准，是用细针插入患者体内以进行放射治疗的小型金属植入物。 尺寸约为3mm。 标记本身很舒服，患者在里面感觉不到它们。 基准点通常用于接受前列腺癌外照射的患者。 它还用于治疗软组织癌，例如肺癌和头颈癌。

市场动态

推动全球基准标记市场的主要因素是癌症发病率激增导致对基准製造商的需求增加、辐射意识提高、新兴国家对医学成像的需求增加以及医疗保健成本增加等。

由于癌症患病率激增，对基准製造商的需求增加预计将推动市场增长。

根据世界卫生组织 (WHO) 的数据，到 2022 年，约有 1000 万人（即约六分之一的死亡人数）将死于癌症，预计到 2020 年癌症将成为全球主要死因。 乳腺癌、肺癌、结肠癌、直肠癌和前列腺癌是最常见的癌症类型。 烟草使用、过度肥胖、饮酒、水果和蔬菜摄入量低以及缺乏运动约占癌症死亡人数的三分之一。 人乳头瘤病毒 (HPV) 和肝炎等致癌感染被认为占低收入和中等收入国家癌症病例的 30%。 通过早期发现和适当的治疗，许多肿瘤是可以治癒的。

根据国家癌症研究所的数据，2020 年美国将有 1,806,590 例新的癌症诊断和 606,520 例癌症死亡。. 最常见的癌症是乳腺癌、肺癌和支气管癌、皮肤黑色素瘤、膀胱癌、非霍奇金淋巴瘤、肾癌和肾盂癌、子宫内膜癌、白血病、胰腺癌、甲状腺癌、肝癌（按降序排列） 2020 年估计患者人数的顺序）。 由于癌症发病率上升，基准生产商进行肿瘤鑑定的潜力正在推动市场。

该产品引起的并发症预计会阻碍市场的增长。

基准标记现在能够最有效地将药物输送到肿瘤，同时对周围健康组织造成的损害最小。 虽然基准标记在放射治疗中具有很大优势，但它们也存在其他风险。

气胸和肺出血是最常见的副作用。 当同时进行 FM 植入和活检取样时，发现问题的风险更高。 肺部病变占问题的大部分，所有肺部病变的 FM 移植都是在 CT 引导下进行的。 自限性气胸、肺出血和咯血属于非严重问题。 最严重的副作用是气胸，需要就医和住院治疗。

COVID-19 影响分析

由于采取了严格的封锁程序和对人员流动的限制，COVID-19 病毒的爆发对基准标记行业的影响微乎其微。 当前的冠状病毒大流行正在损害医疗保健。 COVID-19 大流行不仅对基准製造商市场产生了重大影响，而且对全球医疗保健系统也产生了重大影响。 根据 Cancer Connect 2020 上的一篇文章，达纳—法伯癌症研究所的研究人员诊断出六种最常见的癌症：乳腺癌、结肠癌、肺癌、胰腺癌、胃癌和食道癌。发现在 COVID-19 流行期间癌症减少了 46%。

此外，包括美国疾病控制与预防中心 (CDC) 在内的许多医疗保健专业人员都提倡延迟择期手术、癌症筛查和其他健康预防服务，除非风险大于收益；建议医院做好准备用于护理 -19 名患者的基础设施。 因此，COVID-19 流行病损害了基准生产商的市场。 然而，随着时间的推移，这种情况有望得到改善。 领先的医疗保健公司正在加紧寻找 COVID-19 疫苗和治疗方法，这给世界各地的医院基础设施带来了巨大压力。 儘管如此，随着癌症治疗的继续，基准标记物的市场依然强劲。 但是，其中一些已被重新安排或放弃。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 由于癌症发病率迅速上升，基准製造商的需求不断扩大
      • 辐射意识的提高促进了市场扩张
    • 约束因素
      • 产品引起的并发症预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第7章按产品配置

  • 黄金标记
  • 聚合物标记
  • 碳标记
  • 白金标记
  • 液体标记
  • 其他

第八章应用

  • 放射治疗
  • CT/CBCT 扫描
  • MRI/MEG 检查
  • 内窥镜超声检查
  • 其他

第 9 章按位置

  • 头部和颈部
  • 乳房
  • 肺
  • 腹部
  • 前列腺
  • 其他

第 10 章最终用户

  • 医院
  • 门诊手术诊所
  • 专科诊所
  • 研究所

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • 波士顿科学公司
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Medtronic Plc
  • Nanovi A/S
  • IBA Dosimetry
  • Roper Technologies Inc.
  • Guerbet SA
  • Eckert & Ziegler BEBIG S.A.
  • IZI Medical Products Inc.
  • Naslund Medical AB
  • MediTron SA.

第14章 DataM

简介目录
Product Code: DMMI1830

Market Overview

The global fiducial markers market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Fiducial markers, also referred to as fiducials, are tiny metal implants that are inserted into the body of a patient using a fine needle to direct radiation therapy. They are roughly 3 mm in size. The markers themselves are not uncomfortable, and the patient cannot feel them internally. Patients receiving external beam radiation therapy for prostate cancer are the ones who use fiducials the most frequently. They can, however, also be utilized to direct treatment for additional soft tissue cancer types, such as lung, head, and neck tumors.

Market Dynamics

The major factors driving the global fiducial markersmarket the rising demand for fiducial manufacturers due to a rapid rise in cancer incidences, the market's expansion is being further fuelled by the increased awareness of radiation, rising demand for medical imaging procedures and rising healthcare expenditure in emerging markets.

Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences is expected to drive the market's growth.

According to World Health Organization, in 2022, nearly 10 million deaths, or nearly one in six deaths, will be caused by cancer 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.

And according to National Cancer Institute(U.S.A), in the U.S., there will likely be 1,806,590 new cases of cancer diagnosed in 2020, and there will also likely be 606,520 cancer-related deaths. The most prevalent cancers are breast cancer, lung and bronchus cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order by estimated new cases in 2020). The market is driven by the possibility for the fiducial producers to identify the tumor due to the rise in cancer incidence.

The complications caused by the products are projected to impede the growth of the market.

Fiducial markers has made for the most effective drug delivery to tumors while causing the least amount of damage to surrounding healthy tissues. Fiducial markers have certain additional risks, although having a major benefit in radiation therapy procedures.

Pneumothoraces and pulmonary bleeding were the most frequent side effects. The risk of problems was found to be higher when FM implantation and biopsy sampling were done simultaneously. Lung lesions accounted for the majority of the issues, and all FM implantations for lung lesions were performed under CT guidance. Self-limiting pneumothoraces, pulmonary bleeding, and hemoptysis were among the less severe issues. The most severe side effect was a pneumothorax, which necessitated medical attention and hospitalization.

COVID-19 Impact Analysis

Due to strong lockdown procedures and a restricted flow of personnel, the COVID-19 virus epidemic has had a minimal impact on the fiducial markers sector. The current coronavirus pandemic has harmed healthcare. The COVID-19 pandemic has had a huge influence on the market for fiducial manufacturers as well as on the world's healthcare systems. According to an article in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute found that the six most frequent cancer types-breast, colorectal, lung, pancreatic, gastric, and esophageal cancers-had a 46% decline in diagnoses during the COVID-19 pandemic.

Additionally, it was advised to delay elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and to prepare the hospital infrastructure for the care of COVID-19 patients by the Centers for Disease Control and Prevention (CDC) and many other medical professional organizations. The COVID-19 epidemic has thus damaged the market for fiducial producers. However, it is anticipated that things will get better with time. Major healthcare corporations are stepping up their attempts to find potential COVID-19 vaccines and medications, putting tremendous strain on hospital infrastructures worldwide. Despite this, ongoing cancer treatments have kept the market for fiducial markers strong. However, several of the procedures were rescheduled or abandoned.

Segment Analysis

The gold fiducial markers segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The gold fiducial markers segment is the highest market holder in the global fiducial markers market. Gold fiducial markers can also be combined with other metals like titanium, platinum, and nickel for increased effectiveness. For instance, these markers improve visibility in MRI scans when coupled with titanium stripes. Major businesses are increasing their R&D spending to create more efficient products. As an illustration, IBA Dosimetry GmbH introduced the Visicoil linear pure gold fiducial marker, a novel helical-shaped product with a hollow core that lowers the incidence of typical issues such as marker migration and artifacts.

Additionally, in June 2022, Nanovi reported that its liquid fiducial marker, BioXmark, has demonstrated in a clinical study to be technically possible to implant in stomach cancer patients to guide preoperative image-guided radiation therapy (IGRT). It can be difficult to accurately identify the treatment target on daily collected CBCT scans during preoperative IGRT of the stomach. Twelve (12) patients with stomach cancer participated in this clinical investigation from the Amsterdam University Medical Center. The study's objective was to evaluate the technological viability of implanting liquid marker (BioXmark) and gold marker (Visicoil) for preoperative stomach cancer IGRT guidance. The segment drives the market as a response.

Geographical Analysis

North America holds the largest market share in the global Fiducial Markers market.

North America dominates the global fiducial markers market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to factors such as the rising incidence of cancer, the presence of numerous major players, rising spending on research and development, increasing patient awareness and preference for radiotherapy, favorable reimbursement laws, and technological advancements, North America is anticipated to account for a sizeable portion of the global market for fiducial markers.

The American Association for Cancer Research reports that since the 1990s, the age-adjusted total cancer death rate in the U.S. has been consistently falling. The decrease between 1991 and 2019 means avoiding over 3.5 million cancer deaths. As of January 1, 2022, more than 18 million cancer survivors will live in the U.S., an increase of more than a million over the previous three years. The advancements in the fight against cancer have not benefited all American communities equally.

It'll also increase the need for disease treatment and grow the market. In North America, the U.S. holds the largest proportion of the market for fiducial markers. The Fiducial Markers Market in this area is also anticipated to benefit from cutting-edge radiation techniques, imaging modalities, and well-established healthcare infrastructure.

Competitive Landscape

The Fiducial Markers market is moderately competitive with local and global companies' presence such as Boston Scientific Corporation, Medtronic Plc, Nanovi A/S, IBA Dosimetry, Roper Technologies Inc., Guerbet SA, Eckert & Ziegler BEBIG S.A., IZI Medical Products Inc., Naslund Medical AB and MediTron SAand more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, first Prostate Cancer treatments use Nova Fiducial Markers announced by C4 Imaging. The first prostate cancer therapies using Nova, a multimodality fiducial marker created to improve the precision of cancer treatment, have been announced by C4 Imaging LLC.

Boston Scientific Corporation.

Overview:A medical technology company called Boston Scientific Corp. (Boston Scientific) is engaged in the development, production, and commercialization of devices for several interventional medical specialties. Electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery are among the specialties in which the company sells products. All across the world, Boston Scientific provides services to hospitals, clinics, outpatient facilities, and medical offices.

Product Portfolio:

LumiCoil PlatinumFiducial Markers:LumiCoil Platinum Fiducial Markers feature platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT, and MRI procedures. The use of fiducials may lead to more accurate targeting in delivery of radiation.

Theglobal Fiducial Markers marketreport would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences
      • 4.1.1.2. The market's expansion is being further fueled by the increased awareness of radiation
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications caused by the products are expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Composition

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 7.1.2. Market Attractiveness Index, By Product Composition
  • 7.2. Gold Markers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Polymer Markers
  • 7.4. Carbon Markers
  • 7.5. Platinum Markers
  • 7.6. Liquid Markers
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Radiation Therapy
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. CT and CBCT Scans
  • 8.4. MRI and MEG Scans
  • 8.5. Endoscopic Ultrasound Scans
  • 8.6. Others

9. By Placement Locations

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 9.1.2. Market Attractiveness Index, By Placement Location
  • 9.2. Head and Neck
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Breast
  • 9.4. Lung
  • 9.5. Abdomen
  • 9.6. Prostate
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 10.3. Ambulatory Surgical Clinics
  • 10.4. Specialty Clinics
  • 10.5. Research Institutions

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boston Scientific Corporation
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Medtronic Plc
  • 13.3. Nanovi A/S
  • 13.4. IBA Dosimetry
  • 13.5. Roper Technologies Inc.
  • 13.6. Guerbet SA
  • 13.7. Eckert & Ziegler BEBIG S.A.
  • 13.8. IZI Medical Products Inc.
  • 13.9. Naslund Medical AB
  • 13.10. MediTron SA.

LIST NOT EXHAUSTIVE

14. Global Fiducial Markers Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us